{"url_path":"/sec/telo/8-k/2026-06-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1971532/0001493152-26-028614-index.html","accession_number":"0001493152-26-028614","cik":"0001971532","ticker":"TELO","issuer_name":"Telomir Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1971532/0001493152-26-028614-index.html","primary_entity_key":"0001971532","primary_entity_name":"Telomir Pharmaceuticals, Inc."},"word_count":247,"has_tables":true,"body_markdown":"**Item\n7.01 Regulation FD Disclosure.**\n\n \n\nOn\nJune 15, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the peer-reviewed publication\nof preclinical data relating to Telomir-Zn in Biomedicine & Pharmacotherapy, in a manuscript entitled “Telomir-Zn Restores\nGlucose Homeostasis and Reduces Insulin Resistance in a Diet-Induced Zebrafish Model of Type 2 Diabetes.”\n\n \n\nThe\npublication reports that Telomir-Zn produced dose-dependent improvements in fasting blood glucose, glucose tolerance, fasting insulin\nlevels, and insulin resistance, as measured by HOMA-IR, in a diet-induced zebrafish model of Type 2 diabetes mellitus. The findings provide\nadditional peer-reviewed evidence supporting Telomir-Zn’s mechanism of action through modulation of intracellular metal homeostasis\nand further expand the scientific foundation underlying the Company’s lead clinical program.\n\n \n\nThe\npublication is the Company’s second peer-reviewed publication in 2026, supporting the biological mechanism of Telomir-Zn. Telomir-Zn\nhas received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration for the Company’s Phase 1/2 clinical\ntrial (TELO-001) in patients with advanced or metastatic triple-negative breast cancer.\n\n \n\nA\ncopy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.\n\n \n\nThe\ninformation contained in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed”\nfor purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into\nany filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing."}